What the changes say
- Aytu Biopharma added four new risks concerning third-party component supply, payor reimbursement, patent litigation, and macroeconomic volatility.
- The company highlighted ongoing EXXUA commercialization and updated significant shareholder ownership stakes.
What changed since the prior 10-K
New
- NewRisks Related to Commercialization
We may not be able to meet the demand for our products if one or more of any third-party manufacturers is unable to supply us with the necessary components that meet our specifications. It may be difficult to find alternate suppliers for any of our products in a timely manner and on terms acceptable to us
We depend on third-party manufacturers to comply with FDA Quality System Regulations, and any failure or unannounced inspection delays could disrupt our product supply and commercialization.
- NewRisks Related to Commercialization
Third-party payors may deny reimbursement for covered products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods, as determined by the third-party payor, or was used for an unapproved indication
Third-party payors and government entities may deny coverage or reduce reimbursement rates for our medical products if they deem them not cost-effective or used for unapproved indications.
- NewRisk Related to Securities Markets and Investment in Our Securities
We are and may become involved in litigation or other proceedings from time to time relating to the enforcement or defense of patent and other intellectual property rights, which could cause us to divert our resources and could put our intellectual property at risk
We face expensive patent infringement litigation, such as our December 11, 2024 lawsuit against Granules Pharmaceuticals in Delaware, which diverts resources and puts our intellectual property at risk.
- NewRisk Related to Securities Markets and Investment in Our Securities
Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price
Global economic instability, inflation, supply chain disruptions, and geopolitical conflicts could adversely affect our business, financial condition, and stock price.
Dropped
- DroppedRisks Related to Our Business and Financial Position
We are actively engaged in discussions regarding a potential strategic transaction. There can be no assurance that this process will result in the pursuit or consummation of any potential transaction
- DroppedRisks Related to Our Business and Financial Position
we may experience difficulties in preserving the commercially sensitive information that may need to be disclosed to third parties during this process or in connection with an assessment of our strategic options
- DroppedRisks Related to Our Business and Financial Position
If we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired
- DroppedRisks Related to Our Business and Financial Position
See Part I, Item 3, Legal Proceedings for more information on these lawsuits
- DroppedRisks Related to Commercialization
possible termination or non-renewal of agreements by third parties, based on their own business priorities, at times that are costly or inconvenient for us
Discussions regarding potential strategic transactions, asset sales, acquisitions, or mergers.
- DroppedRisks Related to Commercialization
If we do not secure collaborations with strategic partners to test, commercialize and manufacture products, we may not be able to successfully develop products and generate meaningful revenues
Risks of preserving commercially sensitive information during strategic reviews.
- DroppedRisks Related to Commercialization
As a result, collaboration agreements may not lead to development or commercialization of our products in the most efficient manner or at all
- DroppedRisks Related to Commercialization
neither experimental nor investigational
Ineffective internal controls over financial reporting under Sarbanes-Oxley Section 404.
- DroppedRisks Related to Our Organization, Structure and Operation
Our business could be negatively affected as a result of the actions of activist stockholders
- DroppedRisks Related to Our Organization, Structure and Operation
if individuals are elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively and timely implement our strategic plan and create additional value for our stockholders
General references to Legal Proceedings diverting management attention and expenses.
- DroppedRisk Related to Securities Markets and Investment in Our Securities
We do not intend to pay cash dividends on our capital stock in the foreseeable future
- DroppedRisk Related to Securities Markets and Investment in Our Securities
Major bank failure or sustained financial market illiquidity, could adversely affect our business, financial condition and results of operations
- DroppedRisk Related to Securities Markets and Investment in Our Securities
We may be unable to access funds in our deposit accounts on a timely basis. Any resulting need to access other sources of liquidity or short-term borrowing would increase our costs
- DroppedRisk Related to Securities Markets and Investment in Our Securities
Deterioration in general economic conditions in the United States and globally, including the effect of prolonged periods of inflation on our customers and suppliers, could harm our business and results of operations
Reworded
- 92% rewrittenRisks Related to Our Business and Financial Position
We have been and, in the future, may become a defendant in one or more stockholder derivative, class-action, and other litigation, and any such lawsuits may adversely affect our business, financial condition, results of operations and cash flows
Updated to generalize stockholder class-action and derivative litigation risks, removing specific references to the 2022 stock option award lawsuits while adding potential penalties, injunctions, and warrant dilution.
- 75% rewrittenRisks Related to Commercialization
Any of these actions, in combination or alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business
Retained core language regarding product recalls and regulatory violations while modifying the surrounding text.
- 71% rewrittenRisks Related to Our Intellectual Property
A dispute concerning the infringement or misappropriation of our proprietary rights, or the proprietary rights of others could be time consuming and costly, and an unfavorable outcome could harm our business
Updated to explicitly state that we are currently subject to intellectual property litigation, referencing Part I Item 3.
- 60% rewrittenRisks Related to Our Organization, Structure and Operation
Certain of our stockholders own a large percentage of our stock and their interests may conflict with yours
Updated major shareholder ownership percentages and names as of June 30, 2025, listing Nantahala at 12.1%, Stonepine at 10.1%, and Laurence W. Lytton at 5.6%.
Was: Certain of our stockholders own a significant percentage of our stock and may and their interests may conflict with yours
- 57% rewrittenRisks Related to Our Organization, Structure and Operation
We depend on key personnel and attracting qualified management personnel and our business could be harmed if we lose personnel and cannot attract new personnel
Added that we do not maintain key person life insurance and compete for talent against larger companies with greater financial resources.
- 55% rewrittenRisks Related to Commercialization
We are heavily dependent on the commercial success of our commercial products. To date, we have not generated sufficient net revenue from the sales of these products to achieve companywide profitability and we may never achieve or maintain profitability
Updated to note that we are currently launching EXXUA in the United States alongside our pediatric and ADHD product portfolios.
Was: We are heavily dependent on the commercial success of our commercial products. To date, we have not generated sufficient revenues from the sales of these products to achieve companywide profitability and we may never achieve or maintain profitability
- 48% rewrittenRisks Related to Our Organization, Structure and Operation
Public concern over the abuse of medications that are controlled substances, including increased legislative, legal and regulatory action, could negatively affect our business
Added that industry opioid and controlled substance settlements have reached hundreds of millions of dollars, increasing potential legal and financial exposure.
- 43% rewrittenRisks Related to Commercialization
obtain patent and/or other proprietary protection for our products
Retained standard competition and patent protection risks from established pharmaceutical companies.
- 36% rewrittenRisks Related to Our Organization, Structure and Operation
In fiscal 2025, the great majority of our gross revenue and gross accounts receivable were due to four significant customers, the loss of which could materially and adversely affect our results of operations
Was: In fiscal 2024, the great majority of our gross revenue and gross accounts receivable were due to three significant customers, the loss of which could materially and adversely affect our results of operations
- 35% rewrittenRisks Related to Our Organization, Structure and Operation
Our accounts receivable subjects us to credit risk
- 31% rewrittenRisks Related to Our Business and Financial Position
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
- 22% rewrittenRisks Related to Commercialization
We have incurred, and anticipate continuing to incur, significant costs associated with commercialization of our approved products and, if approved, any other product candidates that we may develop. It is possible that we will never attain sufficient product net revenue to achieve profitability
Was: We have incurred, and anticipate continuing to incur, significant costs associated with commercialization of our approved products and, if approved, any other product candidates that we may develop. It is possible that we will never attain sufficient product sales revenues to achieve profitability
- 21% rewrittenRisks Related to Our Business and Financial Position
We have not established sources of ongoing net revenue sufficient to cover operating costs
Was: We have not established sources of ongoing revenue sufficient to cover operating costs
- 21% rewrittenRisk Related to Securities Markets and Investment in Our Securities
Effecting a reverse stock split, if determined by the Board in its discretion, may not achieve one or more of our objectives
All 61 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Business and Financial Position
- 01We have incurred losses to date and can give no assurance of profitability
- 02We have not established sources of ongoing net revenue sufficient to cover operating costs21% rewritten
- 03We may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due
- 04The terms of our loan agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our operating and financial flexibility
- 05Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited31% rewritten
- 06We have been and, in the future, may become a defendant in one or more stockholder derivative, class-action, and other litigation, and any such lawsuits may adversely affect our business, financial condition, results of operations and cash flows92% rewritten
Risks Related to Commercialization
- 07We are heavily dependent on the commercial success of our commercial products. To date, we have not generated sufficient net revenue from the sales of these products to achieve companywide profitability and we may never achieve or maintain profitability55% rewritten
- 08We have incurred, and anticipate continuing to incur, significant costs associated with commercialization of our approved products and, if approved, any other product candidates that we may develop. It is possible that we will never attain sufficient product net revenue to achieve profitability22% rewritten
- 09Our pharmaceutical products may prove to be difficult to effectively commercialize as planned or on the timeframes we announce and expect
- 10We rely on limited sources of supply for our products, and any disruption in the chain of supply may impact production and sales of our products, and cause delays in developing and commercializing our currently manufactured and commercialized products
- 11We rely on third parties to manufacture certain products, and third-party manufacturing risks and inefficiencies may result in costs and delays that prevent us from successfully commercializing products and adversely affect our ability to produce our products
- 12We may not be able to meet the demand for our products if one or more of any third-party manufacturers is unable to supply us with the necessary components that meet our specifications. It may be difficult to find alternate suppliers for any of our products in a timely manner and on terms acceptable to usNew
- 13Any of these actions, in combination or alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business75% rewritten
- 14We face substantial competition, including the introduction of generics, from companies with considerably more resources and experience than we have, which may result in others discovering, developing, receiving approval for, or commercializing products before or more successfully than us
- 15obtain patent and/or other proprietary protection for our products43% rewritten
- 16Government restrictions on pricing and reimbursement, as well as other healthcare payor cost-containment initiatives, may negatively impact our ability to generate net revenue
- 17the availability of capital
- 18Our financial results will depend on the acceptance among clinicians, third-party payors and the medical community of our products
- 19general economic conditions
- 20If third-party payors do not reimburse our customers for the products we sell or if reimbursement levels are set too low for us to sell one or more of our products at a profit, our ability to sell those products and our results of operations will be harmed
- 21Third-party payors may deny reimbursement for covered products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods, as determined by the third-party payor, or was used for an unapproved indicationNew
- 22Reporting and payment obligations under the Medicaid Drug Rebate Program and other governmental drug pricing programs are complex and may involve subjective decisions. Any failure to comply with those obligations could subject us to penalties and sanctions
- 23Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
- 24We are subject to United States and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business
- 25We are subject to various health care fraud and abuse and reimbursement laws pertaining to the marketing of our approved products
- 26Adzenys and Cotempla contain controlled substances, and their manufacture, use, sale, importation, exportation, prescribing and distribution are subject to regulation by the DEA
- 27Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule
- 28The design, development, manufacture, supply and distribution of our products are technically complex and require regulatory compliance
- 29There is a risk we may be unable to sell and distribute certain of our products if we cannot continue to comply with the serialization requirements of the Drug Quality and Security Act within the necessary time frames
- 30Failure to comply with health and data protection laws and regulations could lead to United States federal and state government enforcement actions, including civil or criminal penalties, private litigation, and adverse publicity and could negatively affect our operating results and business
- 31We may use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time-consuming and costly
Risks Related to Our Intellectual Property
- 32A dispute concerning the infringement or misappropriation of our proprietary rights, or the proprietary rights of others could be time consuming and costly, and an unfavorable outcome could harm our business71% rewritten
- 33injunctive or other equitable relief that may effectively block our ability to further develop, commercialize, and sell products; or
- 34We are dependent on our relationships and license agreements, and we rely on the intellectual property rights granted to us pursuant to the license agreements
- 35The expiration or loss of patent protection may adversely affect our future net revenue and operating results
- 36Our ability to compete may decline if we do not adequately protect or enforce our intellectual property rights
- 37If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
- 38We may not be able to enforce our intellectual property rights throughout the world
Risks Related to Our Organization, Structure and Operation
- 39Our efforts to expand and transform our businesses may require significant investments; if our strategies are unsuccessful, our business, results of operations and/or financial condition may be materially adversely affected
- 40difficulties due to lack of or limited prior experience in any new markets we may enter
- 41We may have difficulties integrating acquired businesses or assets and such acquisitions may not result in the anticipated benefits, as a result, our business, results of operations and/or financial condition may be materially adversely affected
- 42In fiscal 2025, the great majority of our gross revenue and gross accounts receivable were due to four significant customers, the loss of which could materially and adversely affect our results of operations36% rewritten
- 43Our accounts receivable subjects us to credit risk35% rewritten
- 44We depend on key personnel and attracting qualified management personnel and our business could be harmed if we lose personnel and cannot attract new personnel57% rewritten
- 45Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our products
- 46We may be subject to legal or administrative proceedings and litigation other than product liability lawsuits which may be costly to defend and could materially harm our business, financial condition and operations
- 47Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us
- 48we may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents
- 49Public concern over the abuse of medications that are controlled substances, including increased legislative, legal and regulatory action, could negatively affect our business48% rewritten
- 50Certain of our stockholders own a large percentage of our stock and their interests may conflict with yours60% rewritten
Risk Related to Securities Markets and Investment in Our Securities
- 51Our failure to meet the continued listing requirements of the Nasdaq could result in a delisting of our common stock
- 52Effecting a reverse stock split, if determined by the Board in its discretion, may not achieve one or more of our objectives21% rewritten
- 53Our share price is volatile and may be influenced by numerous factors, some of which are beyond our control
- 54other events or factors, many of which are beyond our control
- 55If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and any trading volume could decline
- 56Some provisions of our charter documents and applicable Delaware law may discourage an acquisition of us by others, even if the acquisition may be beneficial to some of our stockholders
- 57establishing advance notice requirements for nominations for election to the Board of Directors or for proposing matters that can be acted upon at stockholder meetings
- 58We are and may continue to be subject to short selling strategies
- 59We are and may become involved in litigation or other proceedings from time to time relating to the enforcement or defense of patent and other intellectual property rights, which could cause us to divert our resources and could put our intellectual property at riskNew
- 60Our business and operations would suffer in the event of system failures, cybersecurity attacks, data leakages or other security breaches
- 61Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock priceNew
Other AYTU Biopharma 10-Ks
- FY2026 10-K risk factors59 risks2 dropped5 reworded
Customer concentration increased to five customers representing 83% of fiscal 2026 gross revenue, versus four customers representing 85% previously.
Filed Sep 22, 2026 - FY2024 10-K risk factors71 risks
Aytu relies heavily on commercializing its pediatric and ADHD prescription portfolios amid persistent operating losses and significant accumulated deficits. The company depends on single-source suppliers and third-party manufacturers, posing supply chain and regulatory vulnerabilities. Compliance with DEA regulations for controlled substances and strict healthcare pricing rules are critical to operations.
Filed Sep 26, 2024
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.